01
maj

0

Vi søger 2 studerende, der kunne tænke sig at lave kandidatspeciale indenfor neuroendokrine tumorer.

Kære Kandidatstuderende 

Vi søger 2 studerende, der kunne tænke sig at lave kandidatspeciale indenfor neuroendokrine tumorer. Start efterårssemestret 2021.  Data egner sig til stort forskningskandidatspeciale (25 ECTS point), der forlænges med yderligere 6 mdr., således at det bliver 1 års varighed. Vi forventer at løn de sidste 6 måneder kan finansieres via et pre-graduate scholar-stipendiat fra kræftens bekæmpelse. Det forventes at data vil kunne publiceres i internationalt peer-reviewed tidsskrift med den kandidatstuderende som 1. forfatter. 

Titlerne er:

Overall survival in patients with pancreatic neuroendocrine neoplasms referred to Copenhagen ENETS Centre of excellence in 2000-2020 

Neuroendocrine neoplasms (NENs) are rare often malignant neoplasms that can originate in almost all organs, but primarily in lungs, small intestine and pancreas. The incidence has increased during recent years with an incidence in 2020 of around 1.4 per 100.000 per year. Gastroenteropancreatic NENs are divided into well-differentiated neoplasms, called neuroendocrine tumors (NETs), and poorly differentiated neoplasms, called neuroendocrine carcinomas (NECs). Furthermore, NETs are divided into low-grade (G1, proliferation index Ki-67 <3%), medium-grade (G2, Ki-67 3-20%) and high-grade tumors (G3, Ki-67> 20%) according to the Ki-67 proliferation index. The grade has a huge impact on prognosis and allocation of treatment. Most pancreatic NENs are G2. Due to the rarity of pancreatic NENS there are limited data on prognosis and limited data on development in prognosis over time 

Department of Endocrinology and Department of Oncology at Rigshospitalet takes care of all patients with suspected or histological proven pancreatic NEN in the Capital Region and Region Zealand. The primary aim of the study is to investigate overall survival of pancreatic NENs referred to the NET center at Rigshospitalet from 2000-2020. Secondary endpoints will be changes in survival over time, identification of prognostic factors (histological grade, differentiation, stage at diagnosis, localization of the primary tumor in pancreas, functioning/non-functioningsurgical resection of primary tumor and/or metastases, immunohistochemistry, circulating tumor marker (chromogranin A) as well as impact of treatment. It is a retrospective study involving approximately 400 patients  

Overall survival in patients with small intestinal neuroendocrine neoplasms referred to Copenhagen ENETS Centre of excellence in 2000-2020 

Neuroendocrine neoplasms (NENs) are rare often malignant neoplasms that can originate in almost all organs, but primarily in lungs, small intestine and pancreas. The incidence has increased during recent years with an incidence in 2020 of around 1.8 per 100.000 per year. Gastrointestinal NENs are divided into well-differentiated neoplasms, called neuroendocrine tumors (NETs), and poorly differentiated neoplasms, called neuroendocrine carcinomas (NECs). Furthermore, NETs are divided into low-grade (G1, Ki-67 <3%), medium-grade (G2, Ki-67 3-20%) and high-grade tumors (G3, Ki-67> 20%) according to the Ki-67 proliferation index. The grade has a huge impact on prognosis and allocation of treatment. Almost all small intestinal NENs are G1 or G2. Due to the rarity of small intestinal NENs there are limited data on prognosis and limited data on development in prognosis over time 

Department of Endocrinology and Department of Oncology at Rigshospitalet takes care of all patients with suspected or histological proven small intestinal NEN in the Capital Region and Region Zealand. The primary aim of the study is to investigate overall survival of small intestinal NENs referred to the NET center at Rigshospitalet from 2000-2020. Secondary endpoints will be changes in survival over time, identification of prognostic factors (histological grade, differentiation, stage at diagnosis, carcinoid syndrome/non-syndrome, surgical resection of primary tumor and impact of treatment. It is a retrospective study involving approximately 650 patients. 

VH 

Overlæge, klinisk lektor Ulrich Knigge, og overlæge klinisk lektor Mikkel Andreassen 

NET-centret RH, endokrinologisk klinik  

Mikkel.andreassen.01@regionh.dk 

35457275 eller 21536970